GSA Capital Partners LLP Boosts Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE)

GSA Capital Partners LLP lifted its holdings in Wave Life Sciences Ltd. (NASDAQ:WVEFree Report) by 14.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 63,513 shares of the company’s stock after purchasing an additional 8,255 shares during the quarter. GSA Capital Partners LLP owned 0.05% of Wave Life Sciences worth $521,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. lifted its position in Wave Life Sciences by 23.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,512 shares of the company’s stock worth $37,000 after buying an additional 856 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in Wave Life Sciences by 50.2% in the first quarter. Ameritas Investment Partners Inc. now owns 7,334 shares of the company’s stock worth $45,000 after buying an additional 2,451 shares during the last quarter. Profund Advisors LLC bought a new stake in Wave Life Sciences in the second quarter worth $53,000. Principal Financial Group Inc. bought a new stake in Wave Life Sciences in the second quarter worth $74,000. Finally, Mackenzie Financial Corp lifted its position in Wave Life Sciences by 13.6% in the second quarter. Mackenzie Financial Corp now owns 15,887 shares of the company’s stock worth $79,000 after buying an additional 1,905 shares during the last quarter. 89.73% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Wave Life Sciences

In other news, CFO Kyle Moran sold 17,146 shares of the business’s stock in a transaction dated Wednesday, September 25th. The stock was sold at an average price of $9.00, for a total transaction of $154,314.00. Following the sale, the chief financial officer now owns 19,777 shares in the company, valued at approximately $177,993. The trade was a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Chris Francis sold 36,000 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $576,000.00. The disclosure for this sale can be found here. Insiders have sold 403,690 shares of company stock worth $5,675,883 over the last quarter. Insiders own 29.10% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on WVE shares. B. Riley lifted their target price on Wave Life Sciences from $19.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, November 4th. Wells Fargo & Company lifted their target price on Wave Life Sciences from $11.00 to $22.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 16th. JPMorgan Chase & Co. lifted their target price on Wave Life Sciences from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, October 17th. Leerink Partners lifted their target price on Wave Life Sciences from $20.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Finally, Raymond James upgraded Wave Life Sciences from an “outperform” rating to a “strong-buy” rating and lifted their target price for the stock from $13.00 to $22.00 in a research report on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Wave Life Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $21.89.

Read Our Latest Report on WVE

Wave Life Sciences Price Performance

WVE stock opened at $14.21 on Wednesday. The business has a 50-day moving average price of $10.90 and a 200 day moving average price of $7.60. Wave Life Sciences Ltd. has a 1-year low of $3.50 and a 1-year high of $16.74. The company has a market capitalization of $2.17 billion, a P/E ratio of -12.80 and a beta of -1.20.

About Wave Life Sciences

(Free Report)

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.

Read More

Institutional Ownership by Quarter for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.